Independent Study Validates IceCure's ProSense Cryoablation Is Safe & Effective Outpatient Procedure For Breast Cancer With 96.8% Success Rate
Portfolio Pulse from Benzinga Newsdesk
An independent study conducted in Spain has validated the safety and effectiveness of IceCure Medical Ltd.'s (NASDAQ:ICCM) ProSense Cryoablation system as an outpatient procedure for breast cancer, with a success rate of 96.8%. The study involved women who declined standard surgery and used ProSense for cryoablation treatment. The study concluded that cryoablation could be an alternative treatment to surgery for breast cancer in patients who reject surgery.
October 02, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from the independent study validating the effectiveness of IceCure's ProSense Cryoablation system could potentially boost the company's reputation and increase demand for its product.
The study validates the effectiveness of IceCure's ProSense Cryoablation system, which could potentially lead to increased demand for the product, especially among patients who prefer less invasive treatment options. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100